Patent intelligence · US
US 11497781
Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
Patent details — US 11497781
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 15, 2022
- Expiration
- Nov 10, 2042
- Applicant
- CG ONCOLOGY, INC.
- Claims
- 17
- CPC classes
- A61K, A61K35/761, A61K39/3955, A61P
Quick answer
US 11497781 (Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor) is held by CG ONCOLOGY, INC.. Status: granted. Granted Nov 15, 2022. Expires Nov 10, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CG ONCOLOGY, INC.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K35/761, A61K39/3955, A61P, A61P35/02
More from CG ONCOLOGY, INC.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11497781?
US 11497781 (Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor) is held by CG ONCOLOGY, INC.. Status: granted. Granted Nov 15, 2022. Expires Nov 10, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11497781?
CG ONCOLOGY, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 11497781 expire?
Our index shows an expiration date of Nov 10, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.